|
1
|
Torre LA, Siegel RL, Ward EM and Jemal A:
International variation in lung cancer mortality rates and trends
among women. Cancer Epidemiol Biomarkers Prev. 23:1025–1036. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Midha A, Dearden S and McCormack R: EGFR
mutation incidence in non-small-cell lung cancer of adenocarcinoma
histology: A systematic review and global map by ethnicity
(mutMapII). Am J Cancer Res. 5:2892–2911. 2015.PubMed/NCBI
|
|
3
|
Zhou C, Liu D, Li J, Sun H, Zheng X, Wang
S, Hong G, Mallampati S, Sun H, Zhou X, et al: Chemotherapy plus
dendritic cells co-cultured with cytokine-induced killer cells
versus chemotherapy alone to treat advanced non-small-cell lung
cancer: A meta-analysis. Oncotarget. 7:86500–86510. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Novello S, Barlesi F, Califano R, Cufer T,
Ekman S, Levra MG, Kerr K, Popat S, Reck M, Senan S, et al:
Metastatic non-small-cell lung cancer: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 27
(Suppl 5):v1–v27. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Anastasiadou E, Jacob LS and Slack FJ:
Non-coding RNA networks in cancer. Nat Rev Cancer. 18:5–18. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cheng CJ, Bahal R, Babar IA, Pincus Z,
Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM,
et al: MicroRNA silencing for cancer therapy targeted to the tumour
microenvironment. Nature. 518:107–110. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Christopher AF, Kaur RP, Kaur G, Kaur A,
Gupta V and Bansal P: MicroRNA therapeutics: Discovering novel
targets and developing specific therapy. Perspect Clin Res.
7:68–74. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mo MH, Chen L, Fu Y, Wang W and Fu SW:
Cell-free circulating miRNA biomarkers in cancer. J Cancer.
3:432–448. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kondo N, Toyama T, Sugiura H, Fujii Y and
Yamashita H: miR-206 Expression is down-regulated in estrogen
receptor alpha-positive human breast cancer. Cancer Res.
68:5004–5008. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang L, Liu X, Jin H, Guo X, Xia L, Chen
Z, Bai M, Liu J, Shang X, Wu K, et al: miR-206 inhibits gastric
cancer proliferation in part by repressing cyclinD2. Cancer Lett.
332:94–101. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Han JG, Jiang YD, Zhang CH, Yang YM, Pang
D, Song YN and Zhang GQ: A novel panel of serum
miR-21/miR-155/miR-365 as a potential diagnostic biomarker for
breast cancer. Ann Surg Treat Res. 92:55–66. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang J, Zhang Z, Wang Q, Xing XJ and Zhao
Y: Overexpression of microRNA-365 inhibits breast cancer cell
growth and chemo-resistance through GALNT4. Eur Rev Med Pharmacol
Sci. 20:4710–4718. 2016.PubMed/NCBI
|
|
13
|
Goldstraw P, Crowley J, Chansky K, Giroux
DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L;
International Association for the Study of Lung Cancer
International Staging Committee; Participating Institutions, : The
IASLC lung cancer staging project: Proposals for the revision of
the TNM stage groupings in the forthcoming (seventh) edition of the
TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheng TY, Cramb SM, Baade PD, Youlden DR,
Nwogu C and Reid ME: The international epidemiology of lung cancer:
Latest trends, disparities, and tumor characteristics. J Thorac
Oncol. 11:1653–1671. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Matsuura N, Koh G, Konishi C, Minamino S,
Takahara Y, Harada H, Kodama K and Emoto M: Fulminant onset of
insulin-dependent diabetes with positive anti-GAD antibody titers
during treatment with nivolumab in a patient with NSCLC. Cancer
Immunol Immunother. 67:1417–1424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang Y, Sun Y and Chen H: Effect of tumor
size on prognosis of node-negative lung cancer with sufficient
lymph node examination and no disease extension. Onco Targets Ther.
9:649–653. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Helissey C, Champiat S and Soria JC:
Immune checkpoint inhibitors in advanced nonsmall cell lung cancer.
Curr Opin Oncol. 27:108–117. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu DD, Wu Y, Shen HY, Lv MM, Chen WX,
Zhang XH, Zhong SL, Tang JH and Zhao JH: Exosomes in development,
metastasis and drug resistance of breast cancer. Cancer Sci.
106:959–964. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lynch SM, McKenna MM, Walsh CP and McKenna
DJ: miR-24 regulates CDKN1B/p27 expression in prostate cancer.
Prostate. 76:637–648. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma Z, Ma Y, Xia Q, Li Y, Li R, Chang W,
Chen J, Leng Z and Tao K: MicroRNA-155 expression inversely
correlates with pathologic stage of gastric cancer and it inhibits
gastric cancer cell growth by targeting cyclin D1. J Cancer Res
Clin Oncol. 142:1201–1212. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zoni E, van der Horst G, van de Merbel AF,
Chen L, Rane JK, Pelger RC, Collins AT, Visakorpi T, Snaar-Jagalska
BE, Maitland NJ and van der Pluijm G: miR-25 modulates invasiveness
and dissemination of human prostate cancer cells via regulation of
αv- and α6-integrin expression. Cancer Res. 75:2326–2336. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li M, Liu L, Zang W, Wang Y, Du Y, Chen X,
Li P, Li J and Zhao G: miR365 overexpression promotes cell
proliferation and invasion by targeting ADAMTS-1 in breast cancer.
Int J Oncol. 47:296–302. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fassan M, Baffa R, Palazzo JP, Lloyd J,
Crosariol M, Liu CG, Volinia S, Alder H, Rugge M, Croce CM and
Rosenberg A: MicroRNA expression profiling of male breast cancer.
Breast Cancer Res. 11:R582009. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen Z, Wu Y, Meng Q and Xia Z: Elevated
microRNA-25 inhibits cell apoptosis in lung cancer by targeting
RGS3. In Vitro Cell Dev Biol Anim. 52:62–67. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiang J, Hang JB, Che JM and Li HC: MiR-25
is up-regulated in non-small cell lung cancer and promotes cell
proliferation and motility by targeting FBXW7. Int J Clin Exp
Pathol. 8:9147–9153. 2015.PubMed/NCBI
|
|
28
|
Bai J, Zhang Z, Li X and Liu H:
MicroRNA-365 inhibits growth, invasion and metastasis of malignant
melanoma by targeting NRP1 expression. Cancer Biomark. 15:599–608.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu X and Li Z: The role of miRNAs in
cutaneous squamous cell carcinoma. J Cell Mol Med. 20:3–9. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhu Y, Zhao H, Rao M and Xu S:
MicroRNA-365 inhibits proliferation, migration and invasion of
glioma by targeting PIK3R3. Oncol Rep. 37:2185–2192. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nie J, Liu L, Zheng W, Chen L, Wu X, Xu Y,
Du X and Han W: microRNA-365, down-regulated in colon cancer,
inhibits cell cycle progression and promotes apoptosis of colon
cancer cells by probably targeting Cyclin D1 and Bcl-2.
Carcinogenesis. 33:220–225. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li M, Yang Y, Kuang Y, Gan X, Zeng W, Liu
Y and Guan H: miR-365 induces hepatocellular carcinoma cell
apoptosis through targeting Bcl-2. Exp Ther Med. 13:2279–2285.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu Y, Chu H, Zhou Y, Wang J, Dong C and
Yin R: miR-365 functions as a tumor suppressor by directly
targeting CYR61 in osteosarcoma. Biomed Pharmacother. 98:531–537.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang C, Wang X, Su Z, Fei H, Liu X and Pan
Q: miR-25 promotes hepatocellular carcinoma cell growth, migration
and invasion by inhibiting RhoGDI1. Oncotarget. 6:36231–36244.
2015. View Article : Google Scholar : PubMed/NCBI
|
